Human interferon beta
- Generic Name
- Human interferon beta
- Drug Type
- Biotech
- CAS Number
- 74899-71-1
- Unique Ingredient Identifier
- V9GU1EM8SF
- Background
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.
Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus. Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS). It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.
- Indication
This drug is indicated to treat relapsing forms of Multiple Sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT04521400
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
- Conditions
- Severe Acute Respiratory SyndromeCoronavirus
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 6667
- Registration Number
- NCT04324463
- Locations
- 🇨🇦
Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada
🇧🇷Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil
🇨🇦London Health Sciences Centre, London, Ontario, Canada
Multiple Sclerosis: Chi3L1 and Treatment Efficacy
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 63
- Registration Number
- NCT04289675
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Metastatic MelanomaMetastatic Uveal MelanomaPathologic Stage IIIA Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Mucosal MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT03865212
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
- Conditions
- Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Fundació Institut Germans Trias i Pujol
- Target Recruit Count
- 16
- Registration Number
- NCT02903537
- Locations
- 🇪🇸
ClÃnica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: BIIB017 (Peginterferon beta-1a)
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Biogen
- Registration Number
- NCT02234869
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
- Conditions
- Multiple Sclerosis Relapse
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 534
- Registration Number
- NCT01252355
- Locations
- 🇨🇴
Investigational Site Number 170001, Barranquilla, Colombia
🇨🇴Investigational Site Number 170007, Bogota, Colombia
🇪🇪Investigational Site Number 233002, Tallinn, Estonia
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- Melinda Magyari
- Target Recruit Count
- 10
- Registration Number
- NCT01171209
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
- Conditions
- Acute Respiratory Distress SyndromeAcute Lung Injury
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT00789685
- Locations
- 🇬🇧
Western Infirmary, Glasgow, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
🇬🇧Whittington Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.